Clinical trials: Restenosis, Coronary
Stent Restenosis, Coronary Artery Disease
Effect of Exercise Training in Coronary Artery Disease Patients After Stenting
To determine the effects of exercise training on ankle-brachial index and Quality of Life in coronary artery disease patients after stenting.
- Trial name
- NCT05315193
- Testing
- Structured In-patient and Home plan, Conventional Therapy
- Where
- Pakistan
- Volunteers
- 73 people
- Sponsor
- Riphah International University
Coronary Artery Disease
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®).
- Trial name
- NCT00307047
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 3,687 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Vision II: Evaluation of GALILEO Intravascular Radiotherapy System
To assess the safety and effectiveness of intravascular brachytherapy for the treatment of intrastent restenosis of coronary lesions with the Galileo system
- Trial name
- NCT00180583
- Testing
- Guidant GALILEO Intravascular Radiotherapy System
- Where
- France
- Volunteers
- 268 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases, Coronary Artery Disease
The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions
The registry aims to evaluate the safety, performance and efficacy of the Everolimus-eluting bioresorbable vascular scaffold (BVS) system following rotational atherectomy in patients with complex de novo native coronary artery…
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Myocardial Ischemia, Coronary Disease
- Trial name
- ASSURE ROT (NCT01915420)
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.
Coronary Artery Disease, Coronary Artery Stenosis
ABSORB III Randomized Controlled Trial (RCT)
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS).
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB-III (NCT01751906)
- Testing
- Absorb BVS, XIENCE
- Where
- 192 sites in United States, Australia
- Volunteers
- 2,008 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis
This study consisted of a randomized controlled trial group and a long balloon observation group. In the randomized control group, 280 subjects with in-stent restenosis were planned to be recruited and randomly assigned to the…
- Trial name
- NCT04733443
- Testing
- Biolimus, SeQuent® Please Neo
- Where
- China
- Volunteers
- 310 people
- Sponsor
- JW Medical Systems Ltd
Coronary Artery Disease, Coronary Artery Stenosis
A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native…
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB CHINA (NCT01923740)
- Testing
- XIENCE V EECSS, Absorb BVS System
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Trial name
- XVU-Phase 1 (NCT00676520)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- United States
- Volunteers
- 8,053 people
- Sponsor
- Abbott Medical Devices
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial
To demonstrate the equivalency in in-segment late lumen loss at 8 months between the Endeavor Drug Eluting Coronary Stent System coated with ABT-578 (10 micrograms/mm) and the Cypher Sirolimus-Eluting Coronary Stent System for…
- Trial name
- ENDEAVOR III (NCT00217256)
- Testing
- Percutaneous Coronary Stenting
- Volunteers
- 436 people
- Sponsor
- Medtronic Vascular
Coronary In Sentrestenosis
The Safety and Efficacy of SeQuent® Please in Real World Chinese Coronary Instent Restenosis Patients
The purpose of this study is to evaluate the efficacy and safety of paclitaxel -eluting PTCA- balloon (SeQuent® Please) in real world Chinese Coronary In Sentrestenosis patients
- Trial name
- NCT03624205
- Testing
- paclitaxel-releasing coronary balloon (SeQuent® Please)
- Volunteers
- 520 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Coronary Artery Disease, Coronary Artery Stenosis
Absorb IV Randomized Controlled Trial
ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States.
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- NCT02173379
- Testing
- Absorb BVS, XIENCE
- Where
- 120 sites in United States, Australia and 3 more
- Volunteers
- 2,604 people
- Sponsor
- Abbott Medical Devices
Coronary Restenosis
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I)
The PACCOCATH ISR study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent restenosis.
- Trial name
- NCT00106587
- Testing
- PTCA, paclitaxel coated balloon catheter (device with drug)
- Where
- 5 sites in Germany
- Volunteers
- 52 people
- Sponsor
- University Hospital, Saarland
Coronary Artery Disease
Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France
The objective of this study is to prepare elements of response to the Haute Autorité de Santé (High Health Authority) of France, which is expecting data relating to the routine use of XIENCE V® endoprothesis within the 5 years…
- Trial name
- Far XIENCE V® (NCT00987506)
- Testing
- XIENCE V®
- Where
- 58 sites in France
- Volunteers
- 1,165 people
- Sponsor
- Abbott Medical Devices
Coronary Disease, Coronary Artery Disease
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT01310309)
- Testing
- Coronary artery placement of a drug-eluting stent
- Where
- 23 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Coronary Restenosis
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis
The objective of this study is to evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System as compared to brachytherapy in patients experiencing in-stent restenosis.
- Trial name
- TAXUS V ISR (NCT00287573)
- Testing
- TAXUS Express2, Brachytherapy (beta source)
- Where
- 42 sites in United States, Canada
- Volunteers
- 488 people
- Sponsor
- Boston Scientific Corporation
Coronary Arterial Disease (CAD), Restenosis, Coronary
Restrospective Analysis of MACE in Patients Treated With Drug-elluting Balloons.
Retrospective analysis of data collected in an institutional database of coronary interventions with use of drug-eluting balloons, with a prospective follow-up for major adverse cardiovascular events and living status.
- Conditions
- Coronary Arterial Disease (CAD), Restenosis, Coronary, Bifurcation Coronary Disease
- Trial name
- EASY-DEB (NCT06972225)
- Testing
- DEB
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- Olivier F. Bertrand
Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery
Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention
The goal of this clinical trial is to describe the long-term (≥ 3 years) patency of coronary artery stents following chronic total occlusion percutaneous coronary intervention (CTO PCI).
- Conditions
- Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery, Chronic Total Occlusion (CTO)
- Trial name
- NCT07473596
- Testing
- chronic total occlusion percutaneous coronary intervention (CTO PCI), coronary computed tomography angiography, invasive coronary angiography
- Where
- Finland
- Volunteers
- 294 people
- Sponsor
- Lauri Mansikkaniemi
In Stent Restenosis, Coronary Artery Calcification
IVL for Stent Underexpantsion
The IVL-Dragon Registry was a multicenter study that enrolled consecutive patients with stent underexpansion treated with IVL in high-volume PCI centers.
- Conditions
- In Stent Restenosis, Coronary Artery Calcification, Intravascular Lithotripsy
- Trial name
- IVL-DRAGON (NCT05112250)
- Testing
- Percutaneous Coronary Intervention
- Where
- 16 sites in Poland
- Volunteers
- 62 people
- Sponsor
- Medical University of Silesia
Coronary Restenosis
Treatment of In-Stent Restenosis 2 Study
The aim of this study is to compare the efficacy of sirolimus-eluting balloon catheters (SEB) and iopromide-coated paclutaxel-eluting balloon catheters (PEB) in the treatment of bare metal (BMS) - or drug-eluting stents…
- Trial name
- TIS2 (NCT03667313)
- Testing
- sirolimus-eluting balloon (SEB) MagicTouch, paclitaxel-eluting balloon (PEB) Sequent Please
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- University Hospital Ostrava